ASGCT Announces Joseph C. Glorioso, PhD, as Incoming Editor-in-Chief of Molecular Therapy

The American Society of Gene & Cell Therapy (ASGCT) today announced the appointment of Joseph C. Glorioso, PhD as the next editor-in-chief of the Society’s field-leading academic journal, Molecular Therapy.

Glorioso, a distinguished professor in the Department of Microbiology and Molecular Genetics at the University of Pittsburgh School of Medicine, joins Molecular Therapy for a five-year term at the helm of the publication starting on January 1, 2025.

“I am honored to take on this new role with Molecular Therapy," Glorioso says. "The journal has an incredible legacy, and I look forward to building upon the strengths and ensuring it remains an essential resource for researchers throughout cell and gene therapy.”

Throughout his career, Glorioso has built the cell and gene therapy community’s understanding of herpes simplex virus (HSV). From defining the antiviral immune responses to infection to the application of HSV gene vectors for the treatment of nervous system dis­­­­­eases, Glorioso’s work has been at the forefront of innovative gene vectors and the development of manufacturing methods for Phase I and Phase II human clinical trials in gene therapy.

“We’re thrilled to have a scientist of Dr. Glorioso’s caliber as the next editor-in-chief of Molecular Therapy,” ASGCT President Jeffery Chamberlain, PhD says. “We’re proud of the growth of Molecular Therapy, and Dr. Glorioso’s groundbreaking work in the scientific building blocks at the core of cell and gene therapy are a perfect fit for the journal.”

Glorioso’s upcoming five-year term as editor-in-chief follows the successful leadership tenure of Roland Herzog, PhD, of Indiana University. Under Herzog’s leadership, Molecular Therapy’s impact factor rose above 10 for the first time in the journal’s history. The journal has also published numerous landmark special issues, including Clinical Gene Therapy, Emerging Diseases, and Gene Editing.

“Dr. Glorioso is the perfect leader for the future Molecular Therapy,” Herzog says. “It has been one of the great honors in my career to lead this journal and build the bond between Molecular Therapy and ASGCT. Its great to know that the journal will be in great hands moving forward.”

Molecular Therapy has an impact factor of 12.4, a CiteScore of 17.9, and a time to first decision of 2.66 weeks.

About Molecular Therapy

Molecular Therapy is the leading journal for research in the areas of gene transfer, vector development and design, stem cell manipulation, development of gene-, peptide-, protein-, oligonucleotide-, and cell-based therapeutics to correct genetic and acquired diseases, vaccine development, pre-clinical target validation, safety/efficacy studies, and clinical trials. Molecular Therapy is dedicated to promoting the sciences in genetics, medicine, and biotechnology. Publishing important peer-reviewed research and cutting-edge reviews and commentaries, the journal continues to attract the best material in the field. Molecular Therapy's 2022 impact factor is 12.4.

About the American Society of Gene & Cell Therapy

ASGCT is the leading professional membership organization for gene and cell therapy worldwide. The Society’s members are scientists, physicians, patient advocates, and other professionals who work in a variety of settings including universities, hospitals, government agencies, foundations, biotechnology, and pharmaceutical companies. The mission of ASGCT is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease.

Related Articles